These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7093590)

  • 1. The effect of treatment on the melancholias (depressions).
    Hamilton M
    Br J Psychiatry; 1982 Mar; 140():223-30. PubMed ID: 7093590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind study of imipramine versus phenelzine in Melancholias and Dysthymic Disorders.
    Vallejo J; Gasto C; Catalan R; Salamero M
    Br J Psychiatry; 1987 Nov; 151():639-42. PubMed ID: 3446308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipramine versus phenelzine in melancholias and dysthymic disorders.
    Campbell MJ
    Br J Psychiatry; 1988 Jun; 152():862-3. PubMed ID: 3167488
    [No Abstract]   [Full Text] [Related]  

  • 4. Predictors of antidepressant treatment outcome in melancholia: psychosocial, clinical and biological indicators.
    Vallejo J; Gasto C; Catalan R; Bulbena A; Menchon JM
    J Affect Disord; 1991 Mar; 21(3):151-62. PubMed ID: 1829739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo.
    Stewart JW; McGrath PJ; Quitkin FM; Harrison W; Markowitz J; Wager S; Leibowitz MR
    Arch Gen Psychiatry; 1989 Dec; 46(12):1080-7. PubMed ID: 2686575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An outpatient evaluation of phenelzine and imipramine.
    Davidson J; Raft D; Pelton S
    J Clin Psychiatry; 1987 Apr; 48(4):143-6. PubMed ID: 3549705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission.
    Stewart JW; Tricamo E; McGrath PJ; Quitkin FM
    Am J Psychiatry; 1997 Jan; 154(1):31-6. PubMed ID: 8988955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of phenelzine and imipramine in depressed inpatients.
    Davidson JR; McLeod MN; Turnbull CD; Miller RD
    J Clin Psychiatry; 1981 Oct; 42(10):395-7. PubMed ID: 7026542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyramine sulfate excretion may be a better predictor of antidepressant response than monoamine oxidase activity.
    Stewart JW; Harrison W; Cooper TB; Quitkin FM
    Psychiatry Res; 1988 Aug; 25(2):195-201. PubMed ID: 3051071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.
    Quitkin FM; McGrath PJ; Stewart JW; Harrison W; Wager SG; Nunes E; Rabkin JG; Tricamo E; Markowitz J; Klein DF
    Arch Gen Psychiatry; 1989 Sep; 46(9):787-93. PubMed ID: 2673130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic depression: response to placebo, imipramine, and phenelzine.
    Stewart JW; McGrath PJ; Quitkin FM; Rabkin JG; Harrison W; Wager S; Nunes E; Ocepek-Welikson K; Tricamo E
    J Clin Psychopharmacol; 1993 Dec; 13(6):391-6. PubMed ID: 8120152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.
    McGrath PJ; Stewart JW; Nunes EV; Ocepek-Welikson K; Rabkin JG; Quitkin FM; Klein DF
    Am J Psychiatry; 1993 Jan; 150(1):118-23. PubMed ID: 8417553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of symptoms of atypical depression for differential drug treatment outcome.
    McGrath PJ; Stewart JW; Harrison WM; Ocepek-Welikson K; Rabkin JG; Nunes EN; Wager SG; Tricamo E; Quitkin FM; Klein DF
    J Clin Psychopharmacol; 1992 Jun; 12(3):197-202. PubMed ID: 1629387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.
    Quitkin FM; Stewart JW; McGrath PJ; Liebowitz MR; Harrison WM; Tricamo E; Klein DF; Rabkin JG; Markowitz JS; Wager SG
    Am J Psychiatry; 1988 Mar; 145(3):306-11. PubMed ID: 3278631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with premature medication discontinuation among responders to an MAOI or a tricyclic antidepressant.
    Agosti V; Stewart JW; Quitkin FM; Rabkin JG; McGrath PJ; Markowitz J
    J Clin Psychiatry; 1988 May; 49(5):196-8. PubMed ID: 3366755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroconvulsive therapy and antidepressant drugs in manic-depressive disease. Treatment results at discharge and 3 months later.
    Bratfos O; Haug JO
    Acta Psychiatr Scand; 1965; 41(4):588-96. PubMed ID: 5884008
    [No Abstract]   [Full Text] [Related]  

  • 17. Psychopharmacologic validation of atypical depression.
    Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Tricamo E; Markowitz JS; Klein DF
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):22-5. PubMed ID: 6376483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenelzine versus imipramine for atypical depression.
    Nakdimen KA
    Am J Psychiatry; 1988 Oct; 145(10):1322. PubMed ID: 3421370
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of imipramine and phenelzine on plasma PEA levels.
    McGrath PJ; Cooper TB; Quitkin FM; Klein DF
    Psychiatry Res; 1988 Nov; 26(2):239. PubMed ID: 3237916
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors.
    Thase ME; Frank E; Mallinger AG; Hamer T; Kupfer DJ
    J Clin Psychiatry; 1992 Jan; 53(1):5-11. PubMed ID: 1737741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.